Reviewer's report

Title: Toxic risk for stereotactic body radiotherapy with helical tomotherapy concurrent and following with erlotinib for non-small cell lung cancer patient - case report

Version: 2 Date: 20 October 2010

Reviewer: maria werner-wasik

Reviewer's report:

The manuscript is vastly improved in merit and the authors have responded to the reviewers comments appropriately and extensively. I would still like a review of English language by a fluent English speaker to smooth out some awkward sentences.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have research funding from Genentech, which manufactures erlotinib.